ANTX - an2therapeutics.com Annual Revenue Growth (Last Twelve Months)

Graphic logo of an2therapeutics.com (ANTX)

AN2 Therapeutics, Inc. (ANTX) narrow focus on a single antibiotic creates binary risks, as evidenced by the trailing 12-month sales growth year-over-year. The 0.00 level reflects the state of the parameter, where a price surge is followed by the threat of capital shortages and failed trials. However, the success of the formula will ensure global scaling and high margins in the treatment of rare pulmonary infections.

an2therapeutics.com (ANTX) Sales Growth YoY (Last Twelve Months): for the period 02/11/2024 - 11/19/2026

AN2 Therapeutics Inc (ANTX) - metric breakdowns and financial figures

- current price and projected stock value:
Analysis of all company metrics:AN2 Therapeutics - ANTX
Signature product of AN2 Therapeutics

This indicator measures the dynamics of rolling annual revenue, smoothing out short-term fluctuations to identify a sustainable business development vector. Investors utilize this calculation to assess the company's scalability and determine marginal risks. The current LTM annual sales growth rate is recorded at 0.00. A positive trend here would signify a successful market entry. For AN2 Therapeutics, Inc. (ANTX), the key driver will be the commercialization of innovative drugs targeting severe pulmonary infections.